Welcome to our dedicated page for Dr Reddys Labs news (Ticker: RDY), a resource for investors and traders seeking the latest updates and insights on Dr Reddys Labs stock.
Dr. Reddy's Laboratories (RDY) maintains its position as a global pharmaceutical innovator through strategic developments in generic medicines, biosimilars, and active pharmaceutical ingredients. This news hub provides investors and industry professionals with essential updates on corporate milestones, regulatory filings, and market expansions.
Access real-time information about earnings announcements, partnership agreements, and product pipeline advancements. Our curated collection features official press releases covering FDA approvals, manufacturing facility certifications, and therapeutic area breakthroughs in oncology and gastroenterology.
Monitor critical updates including patent litigation outcomes, emerging market entries, and sustainability initiatives. The repository serves as a reliable resource for understanding RDY's operational strategies and quality compliance across 75+ countries.
Bookmark this page for streamlined access to verified updates about Dr. Reddy's Laboratories. Check regularly for insights into biosimilar developments, API production innovations, and financial performance indicators shaping the global pharmaceutical landscape.
Dr. Reddy’s Laboratories has acquired a portfolio of branded and generic injectable products from Eton Pharmaceuticals for approximately $5 million upfront, with potential contingent payments of $45 million. The acquisition includes the NDAs for Biorphen® and Rezipres® injections and aims to enhance Dr. Reddy’s institutional business in the U.S. market, where the total addressable market for these products is estimated at $174 million for the year ending April 2022. This move supports Dr. Reddy’s commitment to expanding affordable medications.
Dr. Reddy’s Laboratories Ltd. has launched Sorafenib Tablets, USP, a generic equivalent of Nexavar (sorafenib) in the U.S. market following approval from the U.S. Food and Drug Administration (USFDA). The 200 mg tablets are available in bottles of 120. CEO Marc Kikuchi emphasized the company's commitment to providing affordable medicines. This launch enhances Dr. Reddy's offerings in the oncology segment, expanding their portfolio aimed at improving patient access to critical treatments.
Dr. Reddy's Laboratories Ltd. has launched Pemetrexed for Injection in 100 mg and 500 mg single-dose vials, approved by the USFDA. This generic version is an equivalent to ALIMTA®, which generated approximately $1.24 billion in US sales for the twelve months ending March 2022. The introduction of this generic product expands Dr. Reddy's offerings in oncology and positions the company in a significant market segment, potentially benefiting its financial growth.
Dr. Reddy's Laboratories and Senores Pharmaceuticals announced the launch of Ketorolac Tromethamine Tablets USP, 10 mg in the U.S., a generic equivalent of Toradol. This nonsteroidal anti-inflammatory drug (NSAID) is indicated for short-term management of acute pain. The U.S. market for Toradol tablets had sales of approximately $16.8 million in the past year. The product is available in bottles of 100, enhancing Dr. Reddy's portfolio in the U.S. market.
Dr. Reddy’s Laboratories has launched Posaconazole Delayed-Release Tablets, a generic equivalent to NOXAFIL®, approved by the U.S. FDA. The product is now available in 100 mg strength, with U.S. sales of NOXAFIL® reaching approximately $140.8 million over the past year. This move supports Dr. Reddy’s commitment to providing affordable, innovative medicines. The tablets come in a bottle count of 60.
Dr. Reddy’s Laboratories has launched Methylprednisolone Sodium Succinate for Injection, a generic version of SOLU-MEDROL® in the U.S., approved by the USFDA. The brand and its generic have recorded U.S. sales of approximately $144 million over the last twelve months ending February 2022, according to IQVIA Health. This product is available in both single-dose and multi-dose vials. Dr. Reddy’s focuses on providing affordable medicines and operates in major markets including the U.S., India, and Europe.
Dr. Reddy's (NYSE:RDY) has launched medical cannabis products in Germany through an exclusive distribution agreement with MediCane. This partnership, established in 2021, allows Dr. Reddy's to market MediCane's products while also co-funding a phase II clinical trial targeting Behavioral and Psychological Symptoms of Dementia (BPSD). With Germany's medical cannabis market growing, valued at ~122 million euros and expanding at a ~25% growth rate, this alliance positions Dr. Reddy's to significantly impact the European market, capitalizing on increasing patient demand.
Dr. Reddy's Laboratories Ltd. has launched its authorized generic version of VASOSTRICT® (vasopressin injection, USP) in the U.S. This release, approved by the U.S. Food and Drug Administration, responds to a significant market demand, with the VASOSTRICT® brand generating approximately $878.5 million in U.S. sales over the past twelve months ending December 2021.
The product is supplied in a carton of 25 single-dose vials, each containing vasopressin 1 mL at 20 units/mL. This launch is particularly relevant during the ongoing COVID-19 pandemic.
Dr. Reddy's Laboratories has announced its definitive agreement to acquire Nimbus Health GmbH, a licensed pharmaceutical wholesaler based in Germany, focusing on medical cannabis. This acquisition involves an upfront payment and performance-based earn-outs expected over the next four years. With a growing medical cannabis market in Germany, currently valued at ~€122 million and experiencing significant growth, this strategic move aims to leverage Nimbus Health's strengths in serving patients with unmet medical needs. The transaction is subject to customary closing conditions.
